Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
FDA Grants Dacomitinib a Priority Review for Lung Cancer Treatment
April 4th 2018The Food and Drug Administration (FDA) granted priority review to dacomitinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations, according to Pfizer, the drug’s manufacturer.
Read More
Only Certain Gynecologic Malignancies Benefit from Immunotherapy
April 2nd 2018As checkpoint inhibitors have changed the treatment landscape for many cancers, three specific biomarkers identified a subgroup of women with cervical and ovarian cancer tumor types who may benefit from such therapies.
Read More
Women with Recurrent Ovarian Cancer Should Be Screened for Various Biomarkers
March 29th 2018Although genomic profiling successfully identifies those with microsatellite instability status who may benefit from PD-1 inhibitor therapy, a vast amount of women may be missed if they are not also tested for high tumor mutation burden too.
Read More
Tony Beasley has spent years in the MLB as a third-base coach for the Texas Rangers. Little did he know his competitive nature and critical thinking would come in to play in his fight against stage 2 colorectal cancer. Since, Beasley has teamed up with Fight CRC as part of their One Million Strong Campaign to help others do one thing: Develop a mentality to fight.
Read More
Guidelines Equip Patients to Understand Immunotherapy Side Effects
February 20th 2018To help educate patients and enable health care teams to effectively manage these side effects, the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) issued new guidelines on understanding and managing immunotherapy-related toxicities.
Read More
Myeloma Precursor May Cause Disease Progression, Even 30 Years Later
February 19th 2018An abnormal protein found in the blood – called monoclonal gammopathy of undetermined significance (MGUS) – may lead to multiple myeloma progression, even after 30 years of disease stability, according to study results published in the New England Journal of Medicine.
Read More
Hidden Burdens and Trying to Feel Normal: The Effects of an Ovarian Cancer Diagnosis
February 18th 2018After a cancer diagnosis and treatment, one may question when they will actually start to feel “normal” again, whatever that may be. The Ovarian Cancer Prognosis and Lifestyle (OPAL) study set out to help women with ovarian cancer to understand just that.
Read More
Sexual Aids, Resources Are Scarce for Cancer Survivors
February 15th 2018The availability of sexual aids and resources available to cancer survivors at a wide array of cancer centers appeared disappointingly low, according to survey results to be presented at the 2018 Cancer Survivorship Symposium.
Read More
Physical Therapy Helps Women Recover Arm Mobility After Lymph Node Surgery
February 13th 2018“Our take home message here is that all women receiving lymph node dissection, whether it is axillary or sentinel, should receive physical therapy to regain range of motion more quickly after surgery, and thus, help maintain physical functioning,” said Electra D. Paskett, Ph.D., MO.
Read More
Survey Reveals Impairment in Sexual Function Among Germ-Cell Tumor Survivors
February 9th 2018Germ cell tumors are growths that form from reproductive cells, which can be malignant or benign. In men, these tumors typically form in the testicles. The plus side is these tumors tend to respond well to treatment, even when diagnosed at later stages. However, one problem still persists after a cure.
Read More